期刊
INTERNATIONAL JOURNAL OF NANOMEDICINE
卷 13, 期 -, 页码 1495-1504出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/IJN.S157082
关键词
tumor-specific pH-responsive peptide; paclitaxel; superparamagnetic iron oxide nanoparticles; liposome; theranostic efficiency
资金
- National Key Research and Development Program of China [2017YFA0205600]
Background: In the present study, the tumor-specific, pH-responsive peptide H7K(R-2)(2) -modified, theranostic liposome-containing paclitaxel (PTX) and superparamagnetic iron oxide nanoparticles (SPIO NPs), PTX/SPIO-SSL-H(7)k(R-2)(2), was prepared by using H7K(R-2)(2) as the targeting ligand, SPIO NPs as the magnetic resonance imaging (MRI) agent, PTX as antitumor drug. Methods: The PTX/SPIO-SSL-H7K(R-2)(2) was prepared by a thin film hydration method. The characteristics of PTX/SPIO-SSL-H7K(R-2)(2) were evaluated. The targeting effect, MRI, and antitumor activity of PTX/SPIO-SSL-H7K(R-2)(2) were investigated detail in vitro and in vivo in human breast carcinoma MDA-MB-231 cell models. Results: Our results of in vitro flow cytometry, in vivo imaging, and in vivo MR imaging confirmed the pH-responsive characteristic of H7K(R-2)(2) in MDA-MB-231 cell line in vitro and in vivo. The results of in vivo MRI and in vivo antitumor activity confirmed the theranostic effect of PTX/SPIO-SSL-H7K(R-2)(2) in MDA-MB-231 tumor-bearing model. Conclusion: Considering all our in vitro and in vivo results, we conclude that we developed targeting modified theranostic liposome which could achieve both role of antitumor and MRI.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据